Terbium-161 for PSMA-targeted radionuclide therapy of prostate cancer

  • Cristina MüllerEmail author
  • Christoph A. Umbricht
  • Nadezda Gracheva
  • Viviane J. Tschan
  • Giovanni Pellegrini
  • Peter Bernhardt
  • Jan Rijn Zeevaart
  • Ulli Köster
  • Roger Schibli
  • Nicholas P. van der Meulen
Open Access
Original Article
Part of the following topical collections:
  1. Oncology – Genitourinary



The prostate-specific membrane antigen (PSMA) has emerged as an interesting target for radionuclide therapy of metastasized castration-resistant prostate cancer (mCRPC). The aim of this study was to investigate 161Tb (T1/2 = 6.89 days; Eβ͞av = 154 keV) in combination with PSMA-617 as a potentially more effective therapeutic alternative to 177Lu-PSMA-617, due to the abundant co-emission of conversion and Auger electrons, resulting in an improved absorbed dose profile.


161Tb was used for the radiolabeling of PSMA-617 at high specific activities up to 100 MBq/nmol. 161Tb-PSMA-617 was tested in vitro and in tumor-bearing mice to confirm equal properties, as previously determined for 177Lu-PSMA-617. The effects of 161Tb-PSMA-617 and 177Lu-PSMA-617 on cell viability (MTT assay) and survival (clonogenic assay) were compared in vitro using PSMA-positive PC-3 PIP tumor cells. 161Tb-PSMA-617 was further investigated in therapy studies using PC-3 PIP tumor-bearing mice.


161Tb-PSMA-617 and 177Lu-PSMA-617 displayed equal in-vitro properties and tissue distribution profiles in tumor-bearing mice. The viability and survival of PC-3 PIP tumor cells were more reduced when exposed to 161Tb-PSMA-617 as compared to the effect obtained with the same activities of 177Lu-PSMA-617 over the whole investigated concentration range. Treatment of mice with 161Tb-PSMA-617 (5.0 MBq/mouse and 10 MBq/mouse, respectively) resulted in an activity-dependent increase of the median survival (36 vs 65 days) compared to untreated control animals (19 days). Therapy studies to compare the effects of 161Tb-PSMA-617 and 177Lu-PSMA-617 indicated the anticipated superiority of 161Tb over 177Lu.


161Tb-PSMA-617 showed superior in-vitro and in-vivo results as compared to 177Lu-PSMA-617, confirming theoretical dose calculations that indicate an additive therapeutic effect of conversion and Auger electrons in the case of 161Tb. These data warrant more preclinical research for in-depth investigations of the proposed concept, and present a basis for future clinical translation of 161Tb-PSMA-617 for the treatment of mCRPC.


161Tb Auger electrons Prostate cancer PSMA ligands Radioligand therapy 


The prostate-specific membrane antigen (PSMA) is a cell-surface glycoprotein that is expressed in normal prostate tissue and overexpressed in prostate cancer [1, 2]. There are indications that the expression level of PSMA correlates with the stage of the disease and the risk of disease progression [3, 4]. PSMA is, therefore, an interesting target to use for radionuclide therapy of metastasized castration-resistant prostate cancer (mCRPC) [5, 6, 7, 8]. The topic of PSMA targeting became popular with the development of small-molecule-based radioligands [9]. Initial compounds were designed for radioiodination, suitable for nuclear imaging, and the first to be used therapeutically in patients [10]. Subsequently, PSMA ligands were developed with a chelator to allow their use in combination with radiometals for both imaging and therapeutic purposes [5, 8, 11]. PSMA-617 and PSMA I&T, equipped with a DOTA and DOTAGA chelator, respectively, have been used for targeted radionuclide therapy of mCRPC in clinics [7, 12, 13]. For this purpose, they were mostly labeled with 177Lu (T1/2 = 6.65 d; Eβ͞av = 134 keV; Eγ = 113 keV, I = 6.17%, Eγ = 208 keV, I = 10.36%), which is currently the most-often applied radiometal for therapeutic purposes in the clinics [14]. In specific cases, 225Ac-PSMA-617 was employed for the treatment of patients at end-stage without further treatment options [15, 16, 17]. 225Ac decays with a half-life of 10 days, emitting several α- and β¯-particles while decaying via a sequence of radioactive daughter nuclides [18]. Although the results obtained with 225Ac-PSMA-617 were impressive, undesired side effects — referring to irreversible damage of salivary and lacrimal glands — have been reported [17]. The question arises, therefore, whether alternative radiometals could be used for targeted radionuclide therapy of mCRPC which would be potentially more powerful than the currently-employed 177Lu, without causing additional side-effects.

In this work, we investigated 161Tb, a recently-introduced radiolanthanide for therapeutic applications [19]. 161Tb decays with a half-life of 6.89 days to stable 161Dy, while emitting β¯-particles (Eβ͞av = 154 keV) suitable for therapeutic purposes and γ-radiation (Eγ = 49 keV, I = 17.0%; Eγ = 75 keV, I = 10.2%) useful for SPECT imaging. In this regard, 161Tb closely resembles 177Lu, even though the emitted γ-radiation is of lower energy. 161Tb also emits a substantial number of low-energy conversion and Auger electrons, which makes this radionuclide exceptionally interesting for the treatment of disseminated cancers with multiple metastases ranging from a single cell (diameter: ~10 μm) to micro cell clusters (diameter: < 1 mm) [20]. Monte Carlo simulations performed by Hindié et al. to assess the dose delivered to 10-μm spheres revealed a 3.5-fold increased value when using 161Tb as compared to 177Lu [21]. In larger tumors (diameter > 10 mm), the emitted electron energy from 161Tb and 177Lu respectively is almost entirely absorbed, resulting in a 1.3-fold higher absorbed electron energy fraction per decay for 161Tb (total electron emission of 197 keV/decay) compared to 177Lu (147 keV/decay), making 161Tb more potent than 177Lu [21]. An additional advantage of 161Tb over 177Lu may be the existence of diagnostic counterparts, including 152Tb (T1/2 = 17.5 h; Eβ+av = 1140 keV, I = 20.3%) and 155Tb (T1/2 = 5.32 d; Eγ = 87 keV, 32.0%, 105 keV, I = 25.1%) for PET and SPECT imaging respectively, potentially enabling pre-therapeutic dosimetry with chemically identical radiopharmaceuticals [22, 23, 24, 25]. The results of theoretical calculations performed by Champion and co-workers also indicate that 161Tb outperforms other clinically employed (177Lu, 90Y) and non-standard therapeutic radionuclides (47Sc, 67Cu) with regard to the dose delivery to small lesions [21, 26].

The production of 161Tb via the 160Gd(n,γ)161Gd → 161Tb nuclear reaction was previously reported by Lehenberger et al. [19]. At the Paul Scherrer Institute (PSI), the method of processing Gd targets irradiated in high neutron flux reactors (RHF, Institut Laue-Langevin, Grenoble, France or SAFARI-1, Necsa, Pelindaba, South Africa) or at a spallation neutron source (SINQ, PSI, Switzerland) was implemented some years ago [22]. The chemical separation of 161Tb from the target material has since been further developed and optimized at PSI.

The topic of the present study was to investigate 161Tb with regard to its application for radionuclide therapy. 161Tb was, therefore, used to label PSMA-617 to enable preclinical comparison with 177Lu-PSMA-617. The in-vitro experiments and biodistribution studies in PC-3 PIP/flu tumor-bearing mice were performed to confirm equal chemical and pharmacokinetic properties of 161Tb-PSMA-617 and 177Lu-PSMA-617 respectively. Importantly, the effect of 161Tb-PSMA-617 was compared to that obtained with 177Lu-PSMA-617 by means of in-vitro cell viability and survival assays, and the therapeutic effect of 161Tb-PSMA-617 was shown in vivo using tumor-bearing mice.

Materials and methods

Production and chemical separation of 161Tb

161Tb was produced as previously reported [22]. Enriched 160Gd targets were irradiated over a period of 1–2 weeks at the SAFARI-1 reactor at Necsa, Pelindaba, South Africa, or at the RHF at Institut Laue–Langevin, Grenoble, France. In some cases, 3-week irradiations were performed at the spallation-induced neutron source SINQ, PSI, Switzerland. 161Tb was chemically separated from the Gd target material and impurities by cation exchange chromatography, using an optimized method of the previously-published process (Supplementary Material) [19, 22].

Preparation and in-vitro evaluation of 161Tb-PSMA-617

The radiolabeling of PSMA-617 (Advanced Biochemical Compounds, ABX GmbH, Radeberg, Germany) with 161Tb was performed under standard labeling conditions (Supplementary material). The stability of 161Tb-PSMA-617, incubated in saline (250 MBq/500 μL), was investigated over a period of 24 h at room temperature (Supplementary material). The n-octanol/PBS distribution coefficient (logD) was determined for 161Tb-PSMA-617 (Supplementary material). All of these experiments were performed as previously reported for 177Lu-PSMA-617 [27].

Tumor cell uptake and internalization studies

Uptake and internalization studies of 161Tb-PSMA-617 and 177Lu-PSMA-617 were performed, as previously reported, using PSMA-positive PC-3 PIP and PSMA-negative PC-3 flu tumor cells (provided by Prof. Dr. Martin Pomper; John Hopkins University, Baltimore, USA) (Supplementary material) [27].

Cell viability assay (MTT assay) and cell survival assay (clonogenic assay)

Tumor cell viability of PC-3 PIP/flu tumor cells upon exposure to 161Tb-PSMA-617 and 177Lu-PSMA-617 (0.01–20 MBq/mL) was assessed using a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, as described by Mosmann [28], and performed according to a previously-reported procedure [29]. The survival of PC-3 PIP/flu tumor cells upon exposure to 161Tb-PSMA-617 and 177Lu-PSMA-617 (0.01–10 MBq/mL) was determined using the clonogenic assay, as described by Franken et al. [30], and performed according to a previously-reported procedure [31]. The detailed methods of these studies, including dosimetric calculations, are described in the Supplementary material. The results were analyzed for statistical significance by a two-way ANOVA with Sidak’s multiple comparison post-test using Graph Pad Prism (version 7).

In-vivo studies

In-vivo experiments were approved by the local veterinarian department and conducted in accordance with the Swiss law of animal protection. Athymic nude BALB/c mice were obtained from Charles River Laboratories (Sulzfeld, Germany) at the age of 5–6 weeks. Mice were subcutaneously inoculated with PC-3 PIP tumor cells (6 × 106 cells in 100 μL Hank’s balanced salt solution (HBSS) with Ca2+/Mg2+) and PSMA-negative PC-3 flu tumor cells (5 × 106 cells in 100 μL HBSS with Ca2+/Mg2+) on the right and left shoulder, respectively, for biodistribution and SPECT imaging studies. Therapy studies were performed with mice inoculated with PC-3 PIP cells (4 × 106 cells in HBSS with Ca2+/Mg2+) on the right shoulder (Supplementary material).

Biodistribution studies

Biodistribution studies were performed 12–14 days after tumor cell inoculation when the tumor xenografts reached an average tumor volume of about ~50–200 mm3 (Supplementary material). PSMA-617 was labeled with 161Tb at a specific activity of 5.0 MBq/nmol and diluted in saline. Tumor-bearing mice were intravenously injected with 161Tb-PSMA-617 (5.0 MBq, 1 nmol, 100 μL). The mice were sacrificed at 1 h, 4 h, 24 h, 48 h, or 96 h post injection (p.i.) and selected tissues and organs were collected, weighed, and measured using a γ-counter (Perkin Elmer, Wallac Wizard 1480). Groups of 3–5 mice were sacrificed at each time point. The results were decay-corrected and listed as percentage of the injected activity per gram of tissue mass (% IA/g). Data are presented as the average ± standard deviation (SD).

The data were compared with those previously obtained for 177Lu-PSMA-617 [27] and analyzed for significance using a one-way ANOVA with Tukey’s multiple comparison post-test using GraphPad Prism software (version 7). A p-value of < 0.05 was considered statistically significant.

Dosimetry estimations

The mean specific absorbed doses (Gy/MBq) to the tumor xenografts and the kidneys were estimated for 161Tb-PSMA-617 and 177Lu-PSMA-617 (Supplementary material). The tissue distribution profile of 161Tb-PSMA-617 was considered as equal to the previously-determined biodistribution data of 177Lu-PSMA-617 [27, 32]. The [% IA/g] values were converted to non-decay corrected values using the respective half-lives of the radionuclides to obtain time-integrated activity to infinity. The mean absorbed energy per decay to cells in the cell viability study was calculated using Monte Carlo simulations with PENELOPE-2014 [33].

SPECT/CT imaging studies

In a separate study, SPECT/CT experiments were performed 12–14 days after tumor cell inoculation using a dedicated small-animal SPECT/CT camera (NanoSPECT/CTTM, Mediso Medical Imaging Systems, Budapest, Hungary) as previously reported (Supplementary material) [34]. 161Tb-PSMA-617 (~25 MBq/nmol) was diluted in saline for injection. Scans were acquired at 1 h, 4 h, and 24 h after injection of the radioligands (~25 MBq, 1 nmol, 100 μL). During the in-vivo scans, mice were anesthetized using a mixture of Isoflurane and oxygen.

Therapy study

Three groups of mice (n = 6) were injected with only saline, 161Tb-PSMA-617 (5.0 MBq; 1 nmol/mouse), or 161Tb-PSMA-617 (10 MBq; 1 nmol/mouse) at Day 0 of the therapy, 6 days after PC-3 PIP tumor cell inoculation (Table 1). The mice were monitored by measuring body weights and the tumor sizes every other day over 12 weeks. Mice were euthanized when pre-defined endpoint criteria were reached, or when the study was terminated at Day 84 (Supplementary material). The relative body weight (RBW) was defined as [BWx/ BW0], where BWx is the body weight in gram at a given day x, and BW0 the body weight in grams at Day 0. The tumor dimension was determined by measuring the longest tumor axis (L) and its perpendicular axis (W) with a digital caliper. The tumor volume (V) was calculated according to the eq. [V = 0.5 * (L * W2)]. The relative tumor volume (RTV) was defined as [TVx/TV0], where TVx is the tumor volume in mm3 at a given day x, and TV0 the tumor volume in mm3 at Day 0.
Table 1

Design of the tumor therapy study

Treatment groups (n = 6)

Injected activity1

Calculated absorbed dose to tumors

Tumor volume

Body weight

Day 0

Day 0







80 ± 17

17 ± 0.4




74 ± 28

17 ± 1.2




88 ± 27

18 ± 1.0*

1The quantity of activity of the injection solutions for each group was confirmed by counting an injection sample (100 μL) using the dose calibrator.

*The average body weight of mice injected with 10 MBq 161Tb-PSMA-617 was significantly higher than the average body weight of mice injected with 5.0 MBq 161Tb-PSMA-617 (p < 0.05).

Assessment of therapy study

The efficacy of the radionuclide therapy was assessed by the tumor growth delay (TGDx), which was calculated as the time required for the tumor volume to increase x-fold over the initial volume at Day 0. The tumor growth delay index [TGDIx = TGDx(T)/TGDx(C)] was calculated as the TGDx ratio of treated mice (T) over control mice (C) for a 2-fold (x = 2, TGD2) and 5-fold (x = 5, TGD5) increase of the initial tumor volume. Statistical analysis was performed by a one-way ANOVA with Tukey’s multiple comparison post-test using GraphPad Prism software (version 7). A value of p < 0.05 was considered statistically significant. The median survival was calculated by Kaplan–Meier curves using GraphPad Prism software (version 7).

Potential early side-effects related to the exposure to radiation were evaluated by the assessment of absolute and relative (to body and to brain) organ weights, selected clinical chemistry plasma parameters including creatinine (CRE), blood urea nitrogen (BUN), alkaline phosphatase (ALP), total bilirubin (TBIL), and albumin (ALB), as well as via histological analysis of bone marrow and salivary glands. The data were analyzed for statistical significance (Supplementary material).

Additional in-vivo investigations using 161Tb-PSMA-617

Additional investigations performed in mice that received 161Tb-PSMA-617 or 177Lu-PSMA-617 (2.5 MBq/mouse, 5.0 MBq/mouse or 10 MBq/mouse) 2 days after PC-3 PIP tumor cell inoculation are reported in the Supplementary material.


Production of 161Tb

No-carrier-added 161Tb was produced at high activities of 6–20 GBq (end of irradiation) depending on the irradiation parameters (neutron flux, irradiation time, and mass of target material). The chemical separation resulted in a radionuclidically pure (160Tb < 0.007%) product of high radiochemical purity comparable to commercial, no-carrier-added 177Lu (Supplementary material, Table S1). 161Tb was made available at a high-activity concentration (10–20 MBq/μL) in SuprapurTM HCl (0.05 M) to be used directly for radiolabeling of PSMA-617.

Radiolabeling, stability and in-vitro properties

Radiolabeling of PSMA-617 with 161Tb was achieved at specific activities up to 100 MBq/nmol at a radiochemical purity of ≥98% (Supplementary material, Fig. S1). 161Tb-PSMA-617 (50 MBq/nmol; 250 MBq/500 μL) was stable over at least 1 h (> 98%), but showed radiolytic degradation when incubated for longer time periods. In the presence of l-ascorbic acid, 161Tb-PSMA-617 was stable up to 24 h (≥ 98%) and did not show any signs of radiolytic degradation (Supplementary material, Fig. S2). The determination of the n-octanol/PBS distribution coefficient (logD value) of 161Tb-PSMA-617 resulted in a value of −3.9 ± 0.1 (Supplementary material).

Internalization studies

The PC-3 PIP tumor cell uptake of 161Tb-PSMA-617 (47–54%) and the internalized fraction (8–11%) after 2–4 h incubation was comparable to the data obtained with 177Lu-PSMA-617 (49–58% and 9–12%, respectively). The uptake in PC-3 flu tumor cells was < 0.5% for both 161Tb-PSMA-617 and 177Lu-PSMA-617, respectively (Supplementary material, Fig. S3).

In-vitro tumor-cell viability and survival

The reduction of viability and survival of PC-3 PIP tumor cells after exposure to 161Tb-PSMA-617 and 177Lu-PSMA-617 correlated with the applied activity concentration. 161Tb-PSMA-617 was significantly more effective in reducing the tumor-cell viability (determined by MTT assays) and survival (determined by clonogenic assays) as compared to 177Lu-PSMA-617 when applied at activity concentrations in the range of 0.1–10 MBq/mL (p < 0.05) and 0.05–5.0 MBq/mL (p < 0.05) respectively (Fig. 1a/b). Under the given experimental conditions, the mean absorbed energy to tumor cells in MTT assays was calculated to be 3.2–4.2-fold higher for 161Tb than for 177Lu. Lower values reflect the situation for cell monolayers, whereas the higher value refers to the “single-cell situation” which was more the case during the treatment, particularly in the setting of the clonogenic assay where the cell number per well was low. The viability of PSMA-negative PC-3 flu cells was not affected when the radioligands were applied at concentrations of up to 10 MBq/mL. Only a slight reduction that was equal for both radioligands (p > 0.05) was detected at the highest concentration (20 MBq/mL). The survival of PC-3 flu cells was, however, affected at radioligand concentrations of 1 MBq/mL and higher, with a tendency of a more pronounced effect from 161Tb-PSMA-617 (p > 0.05) (Fig. 1c/d). The viability and survival of PC-3 PIP tumor cells exposed to 161Tb-DPTA and 177Lu-DTPA were not affected, and showed only a marginal reduction at higher radioligand concentration, which was equal for both radionuclide complexes (p > 0.05) (Fig. 1e/f).
Fig. 1

Results of the PC-3 PIP/flu tumor (a/c/e) cell viability and (b/d/f) survival studies. a, b Percentage of PC-3 PIP tumor cell viability and survival using 161Tb-PSMA-617 and 177Lu-PSMA-617 compared to untreated control cells (set to 100% viability; average ± SD). c, d Percentage of PC-3 flu tumor cell viability using 161Tb-PSMA-617 and 177Lu-PSMA-617 compared to untreated control cells (set to 100% viability; average ± SD). e, f Percentage of PC-3 PIP tumor cell viability using 161Tb-DTPA and 177Lu-DTPA compared to untreated control cells (set to 100% viability; average ± SD). * indicates the range where significantly different data was obtained for 161Tb-PSMA-617 and 177Lu-PSMA-617 (p < 0.05).

Biodistribution studies and dose estimation

Time-dependent biodistribution of 161Tb-PSMA-617 was assessed in PC-3 PIP/flu tumor-bearing mice and compared to the data previously obtained with 177Lu-PSMA-617 (Supplementary material, Table S2) [27, 32]. The uptake of 161Tb-PSMA-617 in PC-3 PIP tumor xenografts reached a maximum at 4 h p.i. (49 ± 5.5% IA/g) and decreased slowly over time (22 ± 4.3% IA/g at 96 h p.i.). Accumulation of 161Tb-PSMA-617 in PC-3 flu tumors and other non-targeted organs was in the range of blood activity levels or below at any evaluated time point. The radioligand was cleared via the kidneys over the first few hours after injection (9.6 ± 1.3% IA/g; 1 h p.i. 2.9 ± 0.14% IA/g; 4 h p.i.). These results confirmed that the tissue distribution profile of 161Tb-PSMA-617 was equal (p > 0.05) to the data previously published for 177Lu-PSMA-617 (Fig. 2) [27, 32].
Fig. 2

Biodistribution data of 161Tb-PSMA-617 in comparison to 177Lu-PSMA-617 in PC-3 PIP/flu tumor-bearing mice until 96 h p.i. (average ± SD, n = 3–5). a Uptake in PC-3 PIP tumors (PSMA positive). b Uptake in PC-3 flu tumors (PSMA negative). c Blood activity levels. d uptake in muscles. e Renal retention and f uptake in the liver.

For the absorbed dose estimations, the absorbed fractions of the assumed spherical tumors (80 mm3) were almost equal, with 0.96 and 0.93 for 161Tb and 177Lu respectively. The estimated mean specific absorbed dose to the PC-3 PIP tumors was 5.34 Gy/MBq and 3.90 Gy/MBq for 161Tb-PSMA-617 and 177Lu-PSMA-617 respectively. This resulted in 27 Gy (5.0 MBq/mouse) and 53 Gy (10 MBq/mouse) in mice treated with 161Tb-PSMA-617, and would result in 20 Gy (5.0 MBq/mouse) and 39 Gy (10 MBq/mouse) if mice were treated with 177Lu-PSMA-617. The mean specific absorbed dose to the kidneys for 161Tb and 177Lu was determined as 0.062 Gy/MBq and 0.045 Gy/MBq respectively, resulting in 0.31 Gy (5.0 MBq/mouse) and 0.62 Gy (10 MBq/mouse) in mice treated with 161Tb-PSMA-617. Should 177Lu-PSMA-617 be used, it would result in a kidney dose of 0.225 Gy (5.0 MBq/mouse) and 0.45 Gy (10 MBq/mouse) respectively.

SPECT/CT imaging

SPECT/CT scans of PC-3 PIP/flu tumor-bearing mice were obtained at 1 h, 4 h, and 24 h after injection of ~25 MBq 161Tb-PSMA-617, resulting in images that were comparable to those previously obtained with 177Lu-PSMA-617 (Fig. 3) [27]. Radioligand accumulation was visualized in the PC-3 PIP tumor xenograft on the right side, while negligible uptake was seen in the PSMA-negative PC-3 flu tumor on the left side. Renal excretion of 161Tb-PSMA-617 was fast and the activity almost entirely excreted after 4 h.
Fig. 3.

SPECT/CT images of mice after injection of ~25 MBq 161Tb-PSMA-617 shown as maximum intensity projections. a Scan obtained 1 h p.i.. b Scan obtained 4 h p.i.. c Scan obtained 24 h p.i..

Preclinical tumor therapy

Constant tumor growth over time was observed in untreated mice of the control group, resulting in three mice that reached the endpoint at Day 18. The tumor growth of mice treated with 5.0 MBq and 10 MBq 161Tb-PSMA-617 was delayed, and hence the first mouse from these groups had to be euthanized at Day 30 and Day 42 respectively. The mice from the group treated with 5.0 MBq 161Tb-PSMA-617 were terminated when the last mouse of the group reached the endpoint at Day 66; however, in the group treated with 10 MBq 161Tb-PSMA-617, two mice were still alive at the end of the study at Day 84 (Table 2; Fig. 4). The tumor response in mice that received 10 MBq 161Tb-PSMA-617 was highly variable among the six mice, ranging from similar effects to those observed after injection of 5.0 MBq 161Tb-PSMA-617 to complete tumor remission (Fig. 5).
Table 2

Various parameters characterizing the efficacy of the treatment


Injected activity

First mouse euthanized

Last mouse euthanized

Median survival













1.0 ± 0.4

1.0 ± 0.1






4.2 ± 1.2

2.5 ± 0.6








1all mice were euthanized at the end of the study at Day 84 even though 2 mice had not reached an endpoint.

Fig. 4

Graphs representing tumor growth and survival of control mice (blue) and mice treated with 161Tb-PSMA-617 (red and dark red) with each group comprising of n = 6 mice. a Average tumor size shown until the first mouse of each group reached an endpoint; untreated control mice (blue), mice injected with 5.0 MBq 161Tb-PSMA-617 (red) and mice injected with 10 MBq 161Tb-PSMA-617 (dark red). b Kaplan–Meier plot with survival curves of control mice (19 days), mice treated with 5.0 MBq 161Tb-PSMA-617 (36 days) and 10 MBq 161Tb-PSMA-617 (65 days)days), respectively.

Fig. 5

Graphs representing individual tumor growth of control mice (blue) and mice treated with 161Tb-PSMA-617 (red and dark red). a Individual mice injected with saline. b Individual mice treated with 161Tb-PSMA-617 (5.0 MBq/mouse). c Individual mice treated with 161Tb-PSMA-617 (10 MBq/mouse).

The median survival time of mice treated with 161Tb-PSMA-617 was 36 days, which was clearly longer than the median survival of the control mice (19 days). The application of 10 MBq 161Tb-PSMA-617 increased the median survival of mice to 65 days. In two of the six cases of this group, the PC-3 PIP tumors disappeared entirely, so that the mice survived over 12 weeks without any signs of tumor regrowth (Figs. 4 and 5).

Monitoring of mice during therapy

In the group of mice that received 10 MBq 161Tb-PSMA-617, the body weight was slightly higher than in the other two groups at therapy start. While control mice and mice that received 5.0 MBq 161Tb-PSMA-617 experienced body weight loss over time, the body weight of mice that received 10 MBq 161Tb-PSMA-617 remained stable (Supplementary material, Table S3). In line with this result, the average absolute organ mass, calculated for kidney, liver and spleen of these mice, were also higher compared to those recorded in mice from the two other groups. The same held true for these organ masses calculated relative-to-body mass and relative-to-brain mass (Supplementary material, Table S3/S4). This indicates that exposure to 161Tb-PSMA-617 at 10 MBq per mouse mitigated the detrimental effects on the general health status observed in the other groups, which were probably caused by the rapidly growing tumors.

Evaluation of selected clinical chemistry parameters of renal and hepatic function (CRE, BUN ALP, TBIL, ALB) and the histological analysis of the bone marrow and salivary glands revealed no meaningful difference between the different groups (Supplementary material, Tables S5/S6).

Additional investigations

A better tumor response to 161Tb-PSMA-617 treatment as compared to 177Lu-PSMA-617 was demonstrated in additional preclinical studies. In this case, mice received the radioligands already 2 days after PC-3 PIP tumor cell inoculation when the tumor tissue was not yet developed (Supplementary material; Table S7; Fig. S4). There was a clear trend of enhanced tumor growth inhibition and increased survival after application of 161Tb-PSMA-617 as compared to 177Lu-PSMA-617 at all activity levels (Supplementary material, Fig. S4/S5, Table S8).


In this study, 161Tb was investigated as a potential alternative to 177Lu to be used in combination with PSMA-targeting ligands. The production of no-carrier-added 161Tb has been developed to a quality that is comparable to that of no-carrier-added 177Lu, enabling efficient radiolabeling of biomolecules under the same experimental conditions. Attempts to label PSMA-617 with 161Tb at specific activities up to 100 MBq/nmol resulted in radiochemically pure 161Tb-PSMA-617 (> 98%). The radiolytic degradation of 161Tb-PSMA-617 was similar to 177Lu-PSMA-617, indicating that the emitted conversion and Auger electrons did not play a critical role with regard to the radioligand’s stability.

In agreement with previously-performed studies that compared 161Tb- and 177Lu-folate conjugates [29], the in-vitro properties of 161Tb-PSMA-617 and 177Lu-PSMA-617 were largely the same. This included the n-octanol/PBS distribution coefficient and cell uptake and internalization in PSMA-positive and PSMA-negative tumor cells. It was also confirmed that the pharmacokinetics of 161Tb-PSMA-617 was equal to 177Lu-PSMA-617, resulting in the same biodistribution profiles as expected (Fig. 2). It is likely that these findings can be extrapolated to any targeting agent with a DOTA-chelator; thus, 161Tb could replace 177Lu for any given biomolecule without changing its pharmacokinetic profile.

The enhanced therapeutic effects of 161Tb compared to 177Lu became obvious from in-vitro data where the exposure to 161Tb-PSMA-617 reduced the viability and survival of PC-3 PIP tumor cells in an activity-dependent manner. In agreement with dosimetric calculations, 161Tb-PSMA-617 was up to 3-fold more effective than 177Lu-PSMA-617 in vitro. This difference in efficacy of 161Tb-PSMA-617 and 177Lu-PSMA-617 was not observed when using PSMA-negative PC-3 flu cells or when PC-3 PIP cells were exposed to the DTPA-complexes of the two radionuclides. These findings confirmed that the observed advantage of using 161Tb-PSMA-617 over 177Lu-PSMA-617 is dependent on PSMA binding and internalization. The in-vitro findings also corroborated previous in-vitro findings, where 161Tb-folate was more effective in reducing KB tumor cell viability than 177Lu-folate [29].

The treatment of PC-3 PIP tumor-bearing mice with 5.0 MBq and 10 MBq 161Tb-PSMA-617, respectively, showed an activity-dependent tumor growth inhibition and prolonged survival of mice. When 161Tb-PSMA-617 was applied at 10 MBq, the tumor xenografts disappeared entirely in two out of six mice, which were still alive at study-end after 12 weeks. As no signs of undesired side-effects were detectable, higher activities may be used to treat the tumors more effectively. The tumor growth inhibition and median survival (TGDI2 = 4.2 ± 1.2; 36 days; Table 2) of mice that received 5.0 MBq 161Tb-PSMA-617 indicated better therapy response that that achieved in previously-reported results obtained with 5.0 MBq 177Lu-PSMA-617 (TGDI2 = 2.1 ± 0.3, median survival: 32 days [34]). Individual mice treated with 5.0 MBq 161Tb-PSMA-617 revealed a heterogeneous response pattern, where the last mouse reached the endpoint at Day 66. In contrast, the use of 177Lu-PSMA-617 therapy resulted in the last mouse to be euthanized at Day 40 [34].

In additional experiments, we simulated the situation of tumor cells in vivo that have not yet grown to a tissue, in order to investigate whether the radioligands delayed the formation of solid tumors (Supplementary material). At that time, a vascularized tissue was not yet developed, and the measurable “swelling” could presumably be ascribed to the formation of a tumor cell cluster. When applied at activities of 2.5 MBq, 5.0 MBq, or 10 MBq, the effect of 161Tb-PSMA-617 was enhanced when compared to that of 177Lu-PSMA-617, and re-growth of already disappeared tumors was less frequent when using 161Tb-PSMA-617 (Supplementary material; Fig. S4; Table S8). These results confirmed the anticipated improved effect of 161Tb over 177Lu also at the level of single cancer cells or cancer cell clusters in vivo.

In line with these results, the dosimetry analysis revealed that 161Tb has a 1.4-fold higher energy deposition in established tumors compared to 177Lu. This ratio increases to about 4-fold for small cell clusters and single cells. Together with the biological results obtained in this study, the dosimetry confirms that 161Tb may be better suited than 177Lu for sterilizing small cell clusters in advanced metastatic prostate cancer with radiolabeled PSMA ligands.

To date, it remains unclear to what extent the design of the targeting ligand could contribute to fully exploiting the decay properties of 161Tb. It has been stated in literature that nuclear localization is necessary to obtain effective Auger electron therapy [35, 36, 37, 38]. In the case of 161Tb, the additional effect is, however, given predominantly by the emission of conversion electrons of an energy and tissue range comparable to β¯-particles of lowest energy. Hence, even when neglecting Auger electrons, the absorbed dose of 161Tb is still superior to that of 177Lu due to more emitted electrons per decay. It remains to be investigated whether PSMA ligands, comprising a nuclear localizing signal for effective delivery of the radionuclide to the cell nucleus, would improve the effect of 161Tb further by also making full use of the emitted Auger electrons. More sophisticated ligand designs and more clinically-relevant mouse models for testing the effects will be the topic of future preclinical studies to obtain answers to these open questions.


161Tb was used for the first time with a PSMA ligand, which demonstrated better results than 177Lu-PSMA-617 in vitro and in vivo. Based on these findings, the postulated superiority of 161Tb over 177Lu was corroborated. Our preclinical research activities will be continued to further investigate 161Tb, as we intend to translate it to clinics and provide prostate cancer patients with an optimized treatment option in the near future.



The authors thank Susan Cohrs and Fan Sozzi for technical assistance of the in-vitro and in-vivo studies, as well as Roger Hasler, Dr. Pascal Grundler, and Dr. Zeynep Talip for assisting the production of 161Tb at PSI (Switzerland); they thank Lebogang Sepini for assistance with the target irradiations at Necsa (South Africa), and Jens Hemmingsson for the assistance of dosimetry calculations at the University of Gothenburg (Sweden). The authors thank Dr. Konstantin Zhernosekov, Isotope Technologies Garching (ITG GmbH; Germany) for providing no-carrier-added 177Lu. Viviane Tschan was funded by the Personalized Health and Related Technologies (PHRT) program of ETH Zurich, Switzerland. Nadezda Gracheva was funded by the Swiss National Science Foundation (IZLIZ3_156800). The production of 161Tb was supported by the NET Research Foundation Petersen Investigator Award 2018 USA.

Compliance with ethical standards

Ethical approval

This study was performed in agreement with the national law and PSI-internal guidelines of radiation safety protection. In-vivo experiments were approved by the local veterinarian department and ethics committee and conducted in accordance with the Swiss law of animal protection.

Conflicts of interest

The authors declare no conflict of interest.

Supplementary material

259_2019_4345_MOESM1_ESM.docx (1.9 mb)
ESM 1 (DOCX 1.93 mb)


  1. 1.
    Silver DA, Pellicer I, Fair WR, Heston WD, Cordon-Cardo C. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res. 1997;3:81–5.Google Scholar
  2. 2.
    Sweat SD, Pacelli A, Murphy GP, Bostwick DG. Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases. Urology. 1998;52:637–40.CrossRefGoogle Scholar
  3. 3.
    Ross JS, Sheehan CE, Fisher HA, Kaufman RP Jr, Kaur P, Gray K, et al. Correlation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancer. Clin Cancer Res. 2003;9:6357–62.Google Scholar
  4. 4.
    Perner S, Hofer MD, Kim R, Shah RB, Li H, Moller P, et al. Prostate-specific membrane antigen expression as a predictor of prostate cancer progression. Hum Pathol. 2007;38:696–701. Scholar
  5. 5.
    Afshar-Oromieh A, Babich JW, Kratochwil C, Giesel FL, Eisenhut M, Kopka K, et al. The rise of PSMA ligands for diagnosis and therapy of prostate cancer. J Nucl Med. 2016;57:79S–89S. Scholar
  6. 6.
    Haberkorn U, Eder M, Kopka K, Babich JW, Eisenhut M. New strategies in prostate cancer: prostate-specific membrane antigen (PSMA) ligands for diagnosis and therapy. Clin Cancer Res. 2016;22:9–15. Scholar
  7. 7.
    Rahbar K, Ahmadzadehfar H, Kratochwil C, Haberkorn U, Schafers M, Essler M, et al. German multicenter study investigating 177Lu-PSMA-617 radioligand therapy in advanced prostate cancer patients. J Nucl Med. 2017;58:85–90. Scholar
  8. 8.
    Eiber M, Fendler WP, Rowe SP, Calais J, Hofman MS, Maurer T, et al. Prostate-specific membrane antigen ligands for imaging and therapy. J Nucl Med. 2017;58:67S–76S. Scholar
  9. 9.
    Kopka K, Benesova M, Barinka C, Haberkorn U, Babich J. Glu-ureido-based inhibitors of prostate-specific membrane antigen: lessons learned during the development of a novel class of low-molecular-weight theranostic radiotracers. J Nucl Med. 2017;58:17S–26S. Scholar
  10. 10.
    Zechmann CM, Afshar-Oromieh A, Armor T, Stubbs JB, Mier W, Hadaschik B, et al. Radiation dosimetry and first therapy results with a 124I/131I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy. Eur J Nucl Med Mol Imaging. 2014;41:1280–92. Scholar
  11. 11.
    Bouchelouche K, Turkbey B, Choyke PL. PSMA PET and radionuclide therapy in prostate cancer. Semin Nucl Med. 2016;46:522–35. Scholar
  12. 12.
    Heck MM, Retz M, D’Alessandria C, Rauscher I, Scheidhauer K, Maurer T, et al. Systemic radioligand therapy with 177Lu labeled prostate specific membrane antigen ligand for imaging and therapy in patients with metastatic castration resistant prostate cancer. J Urol. 2016;196:382–91. Scholar
  13. 13.
    Kulkarni HR, Singh A, Schuchardt C, Niepsch K, Sayeg M, Leshch Y, et al. PSMA-based radioligand therapy for metastatic castration-resistant prostate cancer: the Bad Berka experience since 2013. J Nucl Med. 2016;57:97S–104S. Scholar
  14. 14.
    Banerjee S, Pillai MR, Knapp FF. Lutetium-177 therapeutic radiopharmaceuticals: linking chemistry, radiochemistry, and practical applications. Chem Rev. 2015;115:2934–74. Scholar
  15. 15.
    Kratochwil C, Bruchertseifer F, Giesel FL, Weis M, Verburg FA, Mottaghy F, et al. 225Ac-PSMA-617 for PSMA-targeted alpha-radiation therapy of metastatic castration-resistant prostate cancer. J Nucl Med. 2016;57:1941–4. Scholar
  16. 16.
    Kratochwil C, Bruchertseifer F, Rathke H, Bronzel M, Apostolidis C, Weichert W, et al. Targeted a-therapy of metastatic castration-resistant prostate cancer with 225Ac-PSMA-617: dosimetry estimate and empiric dose finding. J Nucl Med. 2017;58:1624–31. Scholar
  17. 17.
    Kratochwil C, Bruchertseifer F, Rathke H, Hohenfellner M, Giesel FL, Haberkorn U, et al. Targeted alpha-therapy of metastatic castration-resistant prostate cancer with 225Ac-PSMA-617: swimmer-plot analysis suggests efficacy regarding duration of tumor control. J Nucl Med. 2018;59:795–802. Scholar
  18. 18.
    Robertson AK, Ramogida CF, Schaffer P, Radchenko V. Development of 225Ac radiopharmaceuticals: TRIUMF perspectives and experiences. Curr Radiopharm. 2018;11(3):156–72. Scholar
  19. 19.
    Lehenberger S, Barkhausen C, Cohrs S, Fischer E, Grünberg J, Hohn A, et al. The low-energy β and electron emitter 161Tb as an alternative to 177Lu for targeted radionuclide therapy. Nucl Med Biol. 2011;38:917–24.
  20. 20.
    Uusijärvi H, Bernhardt P, Rösch F, Mäcke HR. Forssell-Aronsson E. Electron- and positron-emitting radiolanthanides for therapy: aspects of dosimetry and production. J Nucl Med. 2006;47:807–14.Google Scholar
  21. 21.
    Hindie E, Zanotti-Fregonara P, Quinto MA, Morgat C, Champion C. Dose Deposits from 90Y, 177Lu, 111In, and 161Tb in micrometastases of various sizes: implications for radiopharmaceutical therapy. J Nucl Med. 2016;57:759–64. Scholar
  22. 22.
    Müller C, Zhernosekov K, Köster U, Johnston K, Dorrer H, Hohn A, et al. A unique matched quadruplet of terbium radioisotopes for PET and SPECT and for α- and β-radionuclide therapy: An in vivo proof-of-concept study with a new receptor-targeted folate derivative. J Nucl Med. 2012;53:1951–9.
  23. 23.
    Müller C, Fischer E, Behe M, Köster U, Dorrer H, Reber J, et al. Future prospects for SPECT imaging using the radiolanthanide terbium-155 — production and preclinical evaluation in tumor-bearing mice. Nucl Med Biol. 2014;41:e58–65. Scholar
  24. 24.
    Müller C, Vermeulen C, Johnston K, Köster U, Schmid R, Türler A, et al. Preclinical in vivo application of 152Tb-DOTANOC: a radiolanthanide for PET imaging. EJNMMI Res. 2016;6:35. Scholar
  25. 25.
    Baum RP, Singh A, Benesova M, Vermeulen C, Gnesin S, Köster U, et al. Clinical evaluation of the radiolanthanide terbium-152: first-in-human PET/CT with 152Tb-DOTATOC. Dalton Trans. 2017;46:14638–46. Scholar
  26. 26.
    Champion C, Quinto MA, Morgat C, Zanotti-Fregonara P, Hindie E. Comparison between three promising β¯-emitting radionuclides, 67Cu, 47Sc and 161Tb, with emphasis on doses delivered to minimal residual disease. Theranostics. 2016;6:1611–8.
  27. 27.
    Benesova M, Umbricht CA, Schibli R, Müller C. Albumin-binding PSMA ligands: optimization of the tissue distribution profile. Mol Pharm. 2018;15:934–46. Scholar
  28. 28.
    Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983;65:55–63.CrossRefGoogle Scholar
  29. 29.
    Müller C, Reber J, Haller S, Dorrer H, Bernhardt P, Zhernosekov K, et al. Direct in vitro and in vivo comparison of 161Tb and 177Lu using a tumour-targeting folate conjugate. Eur J Nucl Med Mol Imaging. 2014;41:476–85. Scholar
  30. 30.
    Franken NA, Rodermond HM, Stap J, Haveman J, van Bree C. Clonogenic assay of cells in vitro. Nat Protoc. 2006;1:2315–9. Scholar
  31. 31.
    Reber J, Haller S, Leamon CP, Müller C. 177Lu-EC0800 combined with the antifolate pemetrexed: preclinical pilot study of folate receptor targeted radionuclide tumor therapy. Mol Cancer Ther. 2013;12:2436–45. Scholar
  32. 32.
    Umbricht CA, Benesova M, Schmid RM, Türler A, Schibli R, van der Meulen NP, et al. 44Sc-PSMA-617 for radiotheragnostics in tandem with 177Lu-PSMA-617-preclinical investigations in comparison with 68Ga-PSMA-11 and 68Ga-PSMA-617. EJNMMI Res. 2017;7:9. Scholar
  33. 33.
    Salvat F. PENELOPE2014: A code system for Monte-Carlo simulation of electron and photon transport. OECD/NEA Data Bank NEA/NSC/DOC. 2015;3:
  34. 34.
    Umbricht CA, Benesova M, Schibli R, Müller C. Preclinical development of novel PSMA-targeting radioligands: modulation of albumin-binding properties to improve prostate cancer therapy. Mol Pharm. 2018;15:2297–306. Scholar
  35. 35.
    Ginj M, Hinni K, Tschumi S, Schulz S, Mäcke HR. Trifunctional somatostatin-based derivatives designed for targeted radiotherapy using Auger electron emitters. J Nucl Med. 2005;46:2097–103.Google Scholar
  36. 36.
    Cornelissen B, Vallis KA. Targeting the nucleus: an overview of Auger-electron radionuclide therapy. Curr Drug Discov Technol. 2010;7:263–79.CrossRefGoogle Scholar
  37. 37.
    Costantini DL, McLarty K, Lee H, Done SJ, Vallis KA, Reilly RM. Antitumor effects and normal-tissue toxicity of 111In-nuclear localization sequence-trastuzumab in athymic mice bearing HER-positive human breast cancer xenografts. J Nucl Med. 2010;51:1084–91. Scholar
  38. 38.
    Chen P, Wang J, Hope K, Jin L, Dick J, Cameron R, et al. Nuclear localizing sequences promote nuclear translocation and enhance the radiotoxicity of the anti-CD33 monoclonal antibody HuM195 labeled with 111In in human myeloid leukemia cells. J Nucl Med. 2006;47:827–36.Google Scholar

Copyright information

© The Author(s) 2019

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (, which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Authors and Affiliations

  • Cristina Müller
    • 1
    Email author
  • Christoph A. Umbricht
    • 1
  • Nadezda Gracheva
    • 1
  • Viviane J. Tschan
    • 1
  • Giovanni Pellegrini
    • 2
  • Peter Bernhardt
    • 3
  • Jan Rijn Zeevaart
    • 4
  • Ulli Köster
    • 5
  • Roger Schibli
    • 1
    • 6
  • Nicholas P. van der Meulen
    • 1
    • 7
  1. 1.Center for Radiopharmaceutical Sciences ETH-PSI-USZPaul Scherrer InstituteVilligenSwitzerland
  2. 2.Laboratory for Animal Model Pathology, Institute of Veterinary Pathology, Vetsuisse FacultyUniversity of ZurichZurichSwitzerland
  3. 3.Department of Radiation Physics, Institution of Clinical Science, Sahlgrenska AcademyUniversity of GothenburgGothenburgSweden
  4. 4.RadiochemistrySouth African Nuclear Energy Corporation (Necsa)BritsSouth Africa
  5. 5.Institut Laue-LangevinGrenobleFrance
  6. 6.Department of Chemistry and Applied BiosciencesETH ZurichZurichSwitzerland
  7. 7.Laboratory of RadiochemistryPaul Scherrer InstituteVilligenSwitzerland

Personalised recommendations